Status:
ACTIVE_NOT_RECRUITING
Kaiser Permanente VACCination Improvement With Nudge-based CardiovAscular Targeted Engagement
Lead Sponsor:
Kaiser Permanente
Conditions:
Cardiovascular Diseases
Influenza
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In randomized clinical trials and observational studies, influenza vaccination is effective in reducing influenza-related illness and hospitalizations and potentially cardiovascular (CV) events and mo...
Detailed Description
In randomized clinical trials and observational studies, influenza vaccination is effective in reducing influenza-related illness and hospitalizations and potentially cardiovascular events and mortali...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Active KPNC or KPMAS member
- ≥6 months of continuous health plan coverage and prescription drug benefit before September 1, 2024
- Evidence of member access to the KP HealthConnect® Portal and/or a listed registered email address
- No documented influenza vaccination during the 2024-2025 influenza season prior to randomization
Exclusion
- Unable to receive or opted out of receiving health system messaging
- Other exclusion that prevents messaging outreach.
- Unknown service area or medical center affiliation.
Key Trial Info
Start Date :
September 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2026
Estimated Enrollment :
3668428 Patients enrolled
Trial Details
Trial ID
NCT06571747
Start Date
September 5 2024
End Date
March 31 2026
Last Update
May 15 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente Northern California
Pleasanton, California, United States, 94588
2
Kaiser Permanente Mid Atlantic States
Bethesda, Maryland, United States, 20852